Medication info
Ritamezin Tablets 2.5/850 mg

Ritamezin Tablets 2.5/850 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Kyungdong Pharmaceutical Co., Ltd.
Appearance
Bilateral bright orange oval film-coated tablets
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 201803143 · Approved 2018.07.30 · Insurance code 648104100

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined for each patient based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each ingredient: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy, the initial dose of this medicine is 2.5/500 mg twice daily, 1 tablet per dose, and the dose may be increased to 2.5/1000 mg twice daily, 1 tablet per dose. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. 5. Patients unable to achieve adequate glycemic control with concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Kyungdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help blood sugar control in patients with type 2 diabetes who are following a dietary and exercise regimen. Linagliptin and metformin work together to effectively improve blood sugar levels. This helps maintain the health of those who have difficulty managing blood sugar levels. Therefore, it is used to enhance blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be determined for each patient based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each ingredient: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy for whom adequate glycemic control cannot be achieved with monotherapy, the initial dose of this medicine is 2.5/500 mg twice daily, 1 tablet per dose, and the dose may be increased to 2.5/1000 mg twice daily, 1 tablet per dose. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from concomitant therapy with linagliptin and metformin: Patients switching from concomitant therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with concomitant therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. 5. Patients unable to achieve adequate glycemic control with concomitant therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication is used to control blood sugar. Before taking this medication, you should be aware that a serious side effect known as lactic acidosis can occur. The risk of lactic acidosis is higher when there is a sudden deterioration of kidney function or if there are problems with heart or lung function. This medication should not be given to patients with certain conditions. For example, those with type 1 diabetes, severe kidney impairment, acute infections, or in shock, as well as patients with severely impaired heart or liver function, and women who are pregnant or breastfeeding should not take this medication. Caution is needed when taking this medication alongside drugs that carry a risk of hypoglycemia, especially when used with insulin or sulfonylureas, as hypoglycemic symptoms may occur necessitating dosage adjustments under a doctor’s guidance. Patients with reduced kidney function should undergo regular renal function tests before and during the use of this medication, and it should not be taken if renal function is greatly impaired. Patients with poor cardiac function should also use this drug with caution, and it should be temporarily discontinued if iodine contrast agents are administered during radiological examinations. This medication should be interrupted for a certain period before and after surgery. During the use of this medication, skin conditions such as acute pancreatitis or bullous pemphigoid may arise, so if abdominal pain or skin blisters develop, immediate medical attention should be sought. This medication can lower vitamin B12 levels, so those on long-term treatment are advised to regularly check for vitamin B12 deficiency. This medication may interact with other drugs, so you must inform your doctor or pharmacist of any other medications you are taking. Extra caution is needed when taken with drugs that may affect kidney function. Women who are pregnant or planning to become pregnant are advised not to take this medication, and breastfeeding women should also avoid it. This medication is not recommended for children under 10 years or adolescents aged 10-17, as its safety and efficacy have not been established in these groups. Older adults commonly experience reduced kidney function and should start at the minimal dosage while regularly monitoring kidney function. In case of overdose, serious side effects such as lactic acidosis may occur, so do not exceed the prescribed dosage without consulting a doctor; immediate medical treatment should be sought if an overdose occurs. This medication should be kept out of the reach of children and stored away from moisture.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decrease and deficiency of vitamin B12
  • hypoglycemia
  • taste disturbance
  • cough
  • decreased appetite
Show 100 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypertension
  • pruritus
  • insomnia
  • depression
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • viral upper respiratory infection
  • periodontitis
  • influenza
  • dyspepsia
  • gastritis
  • dizziness
  • drowsiness
  • chest discomfort
  • asthenia
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusion
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Bilateral bright orange oval film-coated tablets

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.